Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications

Hormone receptor-positive breast cancer (HR+ BC) accounts for approximately 75% of new BC diagnoses. Despite the undisputable progresses obtained in the treatment of HR+ BC in recent years, primary or acquired resistance to endocrine therapies still represents a clinically relevant issue, and is lar...

Descripción completa

Detalles Bibliográficos
Autores principales: Zattarin, Emma, Leporati, Rita, Ligorio, Francesca, Lobefaro, Riccardo, Vingiani, Andrea, Pruneri, Giancarlo, Vernieri, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764472/
https://www.ncbi.nlm.nih.gov/pubmed/33316954
http://dx.doi.org/10.3390/cells9122644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764472/
https://www.ncbi.nlm.nih.gov/pubmed/33316954
http://dx.doi.org/10.3390/cells9122644

Ejemplares similares